Testimonials

Small Molecules

Biological Therapeutics

New Targets

Diagnostics

Enabling Technology

Antibody Catalogue

Register

Privileged Access Section

Anti-CD23 Antibody Profile

Antigen: CD23
Relevance: CD23, a low-affinity IgE receptor (Fcepsilon RII), is widely expressed on the surface of a number of cell types. CD23 mediates numerous IgE-related immune responses. Both membrane and soluble CD23 play important roles in allergic responses.
Clone: BU38
Subclass: IgG1
Applications: FACS, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (formalin-fixed paraffin-embedded sections, frozen sections), Western Blot
Immunogen: Myeloma cell line Rob
Reactivity: Human; not yet tested in other species
Species raised in: Mouse
Fusion partner: NSO fusion partner.
Recommended growth conditions: RPMI 1640 + 10% FCS
References:

Aubry, J.P. et al. 1987 Leucocyte Typing III Oxford University Press-Oxford, New York, Tokyo

Chen et al. 2000 Appl Immunohistochem Mol Morphol. 8(1):1-11 PubMed Logo

Bonnefoy, J.Y. et al. 1995 Curr. Opin. Immunol. 7:355–359 PubMed Logo

Hardie, D.L. et al. 1993 Eur. J. Immunol. 23:997–1004 PubMed Logo

Hellen et al. 1991 J Clin Pathol. 44(4):293-6 PubMed Logo

Knapp, W. et al. 1989 Leukocyte Typing IV Oxford University Press

Kroft, S.H. et al. 1998 Mod Pathol 11:967–970 PubMed Logo

Karagiannis et al. 2001 Immunology 103(3):319-31. PubMed Logo

Kumar S et al. 1996 Mod Pathol 9:925–929 PubMed Logo

Maeda, et al. 2002 J Histochem & Cytochem 50(11) 1475–1485 PubMed Logo

Murray, P.G. et al. 1991 J Pathol 165:125–128 PubMed Logo
Rowlands, D.C. et al. 1990 J Pathol 160:239–243
PubMed Logo

Sancho, D. et al. 2000 J.Immunol. 2000, 165: 3868–3875 PubMed Logo

Sano, H. et al. 1999 Proc. Assoc. Am. Physicians 111:82–91 PubMed Logo

Sarsfield et al. 1996 J.Pathol. 180(1):18-25 PubMed Logo

Schlossman, S.F. et al. 1995 Leukocyte Typing V Oxford University Press
Leucocyte Typing VI, Garland Publishing (1998)
Positive Control : Follicular lymphoma or tonsil (mantle cell lymphomas are negative)

For further information about antibodies from CRT or to discuss sales or licensing options, please contact Reagents@cancertechnology.com

Click here to view Notes and Disclaimer information

[back]